Review
Biochemistry & Molecular Biology
Pawel Lukasik, Michal Zaluski, Izabela Gutowska
Summary: Cyclin-dependent kinases are crucial in various cellular processes and their dysregulation can lead to diseases, making them potential drug targets.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Pharmacology & Pharmacy
Hanzhi Liang, Jintong Du, Reham M. Elhassan, Xuben Hou, Hao Fang
Summary: CDK7, a key player in the cell cycle and transcriptional regulation, is considered a promising therapeutic target for cancer treatment. CDK7 selective inhibitors, such as SY-5609 and CT7001, are in clinical development, but challenges including selectivity, side effects, and drug resistance still need to be addressed. Despite these challenges, ongoing clinical development and in-depth analysis of CDK7 inhibitors suggest they will become a promising approach for cancer treatment in the near future.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2021)
Article
Biology
Evan L. Ardiel, Andrew Lauziere, Stephen Xu, Brandon J. Harvey, Ryan Patrick Christensen, Stephen Nurrish, Joshua M. Kaplan, Hari Shroff
Summary: A systematic description of behavioral maturation for Caenorhabditis elegans embryos is presented in this study. Early movement is dominated by flipping between dorsal and ventral coiling, which gradually slows into a period of reduced motility. Late-stage embryos exhibit sinusoidal waves of dorsoventral bends, prolonged bouts of directed motion, and a rhythmic pattern of pausing.
Review
Biochemistry & Molecular Biology
Marika A. V. Reinius, Elizabeth Smyth
Summary: The introduction of CKI inhibitors has been a major development in the treatment of advanced breast cancer, with potential applications beyond metastatic breast cancer treatment. Evidence suggests that these agents have impacts on cancer immunology and metabolism, expanding our understanding of their therapeutic effects. Challenges and opportunities in the 2020s, including treatment resistance and biomarker development, are anticipated in the continued research and application of CKIs.
EXPERT REVIEWS IN MOLECULAR MEDICINE
(2021)
Editorial Material
Chemistry, Medicinal
Mark Klein
Summary: Cyclin-dependent kinases (CDKs) have important roles in normal cells and can be targeted for cancer therapy. CDK4 inhibitors have been approved for advanced breast cancer treatment. However, the development of selective inhibitors for individual CDKs is challenging due to the highly conserved ATP-binding site.
Article
Microbiology
Juri Kim, Eun-Ah Park, Mee Young Shin, Soon-Jung Park
Summary: This study investigated the functional roles of Giardia lamblia CDKs (GlCDKs) and their cognate cyclins. Using morpholino-mediated knockdown and coimmunoprecipitation, the functions of GlCDK1 and GlCDK2 were distinguished. GlCDK1 with Glcyclin 3977 plays a crucial role in flagellum formation and cell cycle control of G. lamblia, while GlCDK2 with Glcyclin 22394/6584 is involved in cell cycle control.
MICROBIOLOGY SPECTRUM
(2023)
Review
Biochemistry & Molecular Biology
Jorrit M. Enserink, Pierre Chymkowitch
Summary: Cdk1 is a master regulator of the cell cycle, controlling progression through different phases. It also directly regulates RNA polymerase activity, which is important for protein synthesis and meeting cellular demands. This regulation promotes cell cycle entry.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Cell Biology
Aleksandra J. Pluta, Cecilia Studniarek, Shona Murphy, Chris J. Norbury
Summary: This article discusses the important roles of structurally related cyclin-dependent protein kinases (CDKs) in eukaryotic cell function, highlighting their roles in cell cycle regulation and transcriptional regulation, and the overlap between these processes.
WILEY INTERDISCIPLINARY REVIEWS-RNA
(2023)
Article
Oncology
Elena Garralda, Alison M. Schram, Philippe L. Bedard, Gary K. Schwartz, Eunice Yuen, Samuel C. McNeely, Silvia Ribeiro, Jason Cunningham, Yi Wang, Arantxa Urunuela, Xiaojian Xu, Patricia LoRusso
Summary: LY3405105 is a promising CDK7 inhibitor with good bioavailability and selectivity. However, the clinical trial showed limited efficacy and no plans for further development. The MTD of LY3405105 monotherapy was determined to be 20 mg QD.
Article
Immunology
Sandro Capellmann, Roland Sonntag, Herdit Schueler, Steffen K. Meurer, Lin Gan, Marlies Kauffmann, Katharina Horn, Hiltrud Koenigs-Werner, Ralf Weiskirchen, Christian Liedtke, Michael Huber
Summary: Mast cells (MCs) are heterogeneous immune cells with different protease repertoires and receptor expressions. A new cell line, PMC-306, derived from primary peritoneal MCs, can be used to study PMC function and tumorigenic processes associated with MC leukemia.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Plant Sciences
Rui-Yi Yang, Jia-Yi Tan, Zhe Liu, Xiao-Ling Shen, Ying-Jie Hu
Summary: The natural lignan LAF from Arctium lappa Linne has been found to inhibit tumor cell growth in vitro and in vivo. However, its role in cell cycle regulation remains unknown.
PHARMACEUTICAL BIOLOGY
(2023)
Article
Microbiology
Yanfei Zhang, Matteo Barberis
Summary: Coordination between cell cycle and metabolism is important for cell division and new cell construction. Cyclin-dependent kinases (Cdks) play a crucial role in this coordination, regulating cell division. This study reveals the possible impact of cell cycle mechanisms on cellular metabolism, finding that certain metabolic enzymes may be phosphorylated by Cdks, affecting their activities and metabolic regulation.
FRONTIERS IN MICROBIOLOGY
(2023)
Article
Pharmacology & Pharmacy
Yanting Zhou, Xiandeng Li, Peifang Luo, Huiting Chen, Yan Zhou, Xueting Zheng, Yuan Yin, Haoche Wei, Hongji Liu, Wen Xia, Mingsong Shi, Xiaoan Li
Summary: CDK4/6 is a crucial player in various cancers and a potential target for anticancer drugs. The interaction between abemaciclib and human CDK6 was studied, and C2231-A was identified as a promising candidate compound with significant inhibitory effects on human breast cancer cell lines.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Pawel Lukasik, Irena Baranowska-Bosiacka, Katarzyna Kulczycka, Izabela Gutowska
Summary: Recent studies have shown that small molecule drugs targeting CDK inhibitors have become attractive options for treating cancer and neurodegenerative disorders. Most CDK inhibitors target the ATP binding pocket, but the similarity in structure among CDK kinases makes achieving selectivity challenging. Therefore, inhibitors binding outside the ATP binding site have attracted great interest for their potential applications in the biomedical field.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Chemistry, Multidisciplinary
Lanlan Fu, Jiajia Mou, Yanru Deng, Xiaoliang Ren, Shuang Qiu
Summary: CDK1 plays an essential role in the cell cycle and has emerged as a new target for cancer therapy. A new series of flavone derivatives, including compound 2a, were discovered as potent CDK1 inhibitors. Compound 2a exhibited strong inhibitory activity against CDK1 and showed potential as a lead compound for CDK1 inhibitor development.
FRONTIERS IN CHEMISTRY
(2022)